Advertisement

Video-Assisted Thoracoscopic Surgery Technique for Pneumonectomy Shown to Be Safe

Advertisement

Key Points

  • Successful video-assisted thoracoscopic surgery (VATS) pneumonectomy rates increased from 50% to 82% by the second half of the series.
  • VATS pneumonectomy did not yield early reductions in pain or incidence of complications, but more patients undergoing VATS were pain-free at 1 year than those who underwent the open technique.
  • Patients who underwent VATS pneumonectomy had a longer median overall survival than those who underwent the open technique.

In the largest series of its kind to date, researchers at Roswell Park Cancer Institute (RPCI) have shown that performing thoracoscopic pneumonectomy, removal of the entire lung through a minimally invasive endoscopic approach, at a high-volume center appears to be safe and may provide pain and survival advantages in the long term. The study by Battoo et al was published in Chest.

“During the past 20 years, portions of the lungs have been removed for lung cancer through lobectomies, and that has been shown to be better done through small incisions or through thoracoscopic lobectomy compared with standard, open lobectomy,” said Todd Demmy, MD, FACS, Clinical Chair of the Department of Thoracic Surgery and Professor of Oncology at RPCI. “We wanted to see if any of the benefits of the lobectomy—which typically involves removal of 20% to 50% of the organ—carry forward when you take the whole lung out in a pneumonectomy.”

Study Dails

Dr. Demmy and his colleagues retrospectively reviewed all patients who underwent pneumonectomy at RPCI from 2002 through 2012. Of the 107 consecutive pneumonectomies performed during this time period, 40 cases were done through an open technique, 50 were done through successful video-assisted thoracoscopic surgery (VATS), and 17 were converted from VATS to an open procedure.

“We performed a relatively large number of pneumonectomies without a significant event in the operating room such as excessive bleeding, which has been one of the major concerns that have prevented other surgeons from trying this technique,” Dr. Demmy said.

By the second half of the series, researchers reported an increase in successful VATS pneumonectomies from 50% to 82%.

Reduced Pain, Improved Survival

In contrast to thoracoscopic lobectomy, which has been associated with dramatic reductions in pain compared with the open technique, VATS pneumonectomy did not yield early reductions in pain or incidence of complications. “But with time, those patients who underwent VATS pneumonectomy tended to have better pain ratings, whereas people who had large incisions with the open technique still had a lot of pain a year later,” Dr. Demmy noted.

At 1 year, 53% of patients who underwent VATS pneumonectomy reported being pain-free compared with 19% of the patients who underwent the open surgical technique. Among patients with early pathologic stage cancer, those who underwent successful VATS pneumonectomy had a longer median survival of 80 months vs 16 months for patients who were converted from VATS to an open procedure and 28 months for those who underwent the open procedure. Among patients with advanced clinical stage disease, those who underwent the VATS procedure had a longer median overall survival of 42 months vs 13 months for those who underwent the open technique.

“Patients who need to undergo pneumonectomy tend to have worse tumors; they often need chemotherapy, and the VATS procedure might help them start chemotherapy or complete it if they have less pain from surgery,” Dr. Demmy said. “Less pain may also reduce the patient’s need for narcotics, and we’re finding now that narcotics may actually have an adverse effect on cancer patients and may increase the growth rate of some tumors, so reducing pain is essential.”

The researchers are continuing to monitor patients who undergo pneumonectomy in a registry, with the ultimate goal of reducing the number of open pneumonectomies they perform.

Dr. Demmy is the corresponding author for the Chest article.

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement




Advertisement